New insider activity at Medpace Holdings ( (MEDP) ) has taken place on November 18, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In recent transactions involving Medpace Holdings stock, Director Robert O. Kraft sold 6,472 shares, amounting to a total of $3,830,453. Meanwhile, CEO August J. Troendle parted with 20,794 shares, generating $12,352,076 from the sale.
Recent Updates on MEDP stock
Recent developments surrounding Medpace Holdings have seen BMO Capital initiate coverage with a Market Perform rating, citing the stock’s full valuation amidst a “tepid” biotech funding environment and potential macroeconomic volatility. Additionally, Medpace has announced updates on several clinical studies, including collaborations with AVM Biotechnology, Telix Pharmaceuticals, and Radiopharm Theranostics. These studies focus on innovative treatments for conditions such as lymphoid malignancies, acute respiratory distress syndrome (ARDS), and advanced cancers. The outcomes of these studies could significantly influence Medpace’s stock performance by boosting investor confidence and positioning the company strategically within the healthcare sector.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 74.98%
Average Trading Volume: 317,744
Technical Sentiment Signal: Buy
Current Market Cap: $16.62B